These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11152580)

  • 1. HIV-Specific CD4(+) and CD8(+) immune responses are generated with a gp120-depleted, whole-killed HIV-1 immunogen with CpG immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Savary J; Carlo DJ
    J Interferon Cytokine Res; 2000 Dec; 20(12):1131-7. PubMed ID: 11152580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
    J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
    Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides.
    Moss RB; Diveley J; Jensen F; Carlo DJ
    Vaccine; 2000 Jan; 18(11-12):1081-7. PubMed ID: 10590329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
    Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
    Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination.
    Lanza P; Moss RB; Giermakowska W; Hancock RB; Richieri SP; Theofa G; Jensen FC; Salk PL; Carlo DJ
    Vaccine; 1998 Apr; 16(7):727-31. PubMed ID: 9562693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
    Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.
    Trabattoni D; Clivio A; Bray DH; Bhagat L; Beltrami S; Maffeis G; Cesana E; Lowry P; Lissoni F; Kandimalla ER; Sullivan T; Agrawal S; Bartholomew R; Clerici M
    Vaccine; 2006 Feb; 24(9):1470-7. PubMed ID: 16221513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency of cell-mediated immune responses to different combined HIV-1 immunogens in a humanized murine model.
    Azizi A; Ghorbani M; Kryworuchko M; Aucoin S; Diaz-Mitoma F
    Hum Vaccin; 2005; 1(4):170-6. PubMed ID: 17012859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model.
    Moss RB; Savary JR; Diveley JP; Jensen F; Carlo DJ
    Immunology; 2002 Aug; 106(4):549-53. PubMed ID: 12153518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
    Zheng H; Zhang H; Liu F; Qi Y; Jiang H
    Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
    Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
    J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha.
    Lekutis C; Shiver JW; Liu MA; Letvin NL
    J Immunol; 1997 May; 158(9):4471-7. PubMed ID: 9127013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of perforin on HIV-1-specific CD8+ lymphocytes after immunization with a gp120-depleted, whole-killed HIV-1 immunogen.
    Moss RB; Giermakowska WK; Wallace MR; Jensen FC; Maigetter RZ; Carlo DJ
    Clin Exp Immunol; 2001 May; 124(2):248-54. PubMed ID: 11422201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
    Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
    J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via immunostimulatory [correction of imunostimulatory] oligonucleotides--relevance to AIDS vaccines in developing countries.
    Ayash-Rashkovsky M; Weisman Z; Diveley J; Moss RB; Bentwich Z; Borkow G
    Vaccine; 2002 Jun; 20(21-22):2684-92. PubMed ID: 12034094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmid DNA containing multiple CpG motifs triggers a strong immune response to hepatitis B surface antigen when combined with incomplete Freund's adjuvant but not aluminum hydroxide.
    Luo Z; Shi H; Zhang H; Li M; Zhao Y; Zhang J; Guo F; Luo S; Sun P; Zhang D; Qian Z; Yang L
    Mol Med Rep; 2012 Dec; 6(6):1309-14. PubMed ID: 22971976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.